Our legacy of achievements
With pride in our achievements in vaccine development over the past 30+ years, we are focused on the future.
Right now, we are working on bringing communities around the globe an even greater degree of protection from infectious disease
2007
First smallpox supply contract with US Government.
2014
Entered collaboration with Janssen for development and supply of Ebola vaccine.
2019
Approval in the US for smallpox & mpox vaccine.
2020
US Commercial team established; acquisition of rabies vaccine, and tick-borne encephalitis vaccine (not available in the US).
2023
Acquisition of typhoid Vaccine, cholera Vaccine, and a phase 3 vaccine candidate for the prevention of chikungunya virus.
2024
Leading pure-play vaccine company with commercial operations in strategic markets, covering a broad product portfolio spanning travel health and public preparedness.
2025
Approval in the US for chikungunya vaccine, in people 12 and over.